Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNeOnc Technologies Holdings, Inc. Common Stock

NeOnc Technologies Holdings, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.55 USD 0.03 ( 0.66%)
Last update at 2026-11-12T15:46:00Z
VOLUME
69227
Market Cap
95.35M

Momentum Score

…

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.33
Low
4.69
High
52 Week Price Range
3.00
Low
12.99
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
4.52
Dividend Yield
-
Revenue TTM
0.04M
Revenue Per Share
0.00
Gross Profit TTM
0.04M
Debt / Equity
-0.36
ROE
-
Net Debt
6.26M
ROCE
346.41%
Diluted EPS TTM
-1.85

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -62.15M -11.90M -14.92M -3.05M -3.38M
Net income -62.15M -11.90M -14.92M -3.05M -3.38M
Selling general administrative 42.85M 3.64M 3.40M 1.69M 2.60M
Gross profit 0.04M 0.08M 0.07M 0.02M -
Reconciled depreciation 0.04M 0.25M 0.00M - -
Ebit -59.64M -9.34M -12.20M -2.84M -3.27M
Ebitda -59.61M -9.10M -12.20M -2.85M -3.26M
Depreciation and amortization 0.04M 0.25M - - -
Operating income -58.17M -7.14M -12.20M -2.84M -3.27M
Other operating expenses 58.21M 7.23M 12.27M 2.86M 3.27M
Interest expense 2.50M 2.70M 2.72M 0.20M 0.11M
Interest income 0.33M 0.02M 0.00M - -
Net interest income -3.29M -2.69M -2.72M -0.20M -0.11M
Total revenue 0.04M 0.08M 0.07M 0.02M 0.00M
Total operating expenses 58.21M 7.23M 12.27M 2.86M 3.27M
Cost of revenue - - 2.74M - -
Total other income expense net -3.98M -4.76M -2.72M -0.21M -0.10M
Net income from continuing ops -62.15M -11.90M -14.92M -3.05M -3.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2.82M 3.42M 1.27M 0.73M 0.03M
Intangible assets 0.50M - - - -
Other current assets 1.33M 1.98M 1.23M 0.10M 0.01M
Total liab 20.33M 8.92M 15.25M 2.30M 2.65M
Total stockholder equity -17.51M -5.50M -13.99M -1.58M -2.62M
Other current liab 6.90M 5.35M 5.69M 0.41M 0.46M
Common stock 0.00M 0.00M 0.00M 0.00M 0.06M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.06M
Retained earnings -112.75M -50.61M -38.71M -23.79M -20.74M
Cash 0.06M 0.06M 0.03M 0.63M 0.03M
Total current liabilities 20.04M 8.92M 15.25M 2.30M 2.65M
Current deferred revenue - - - 0.50M 0.50M
Net debt 6.26M -0.04M 6.57M -0.58M 1.12M
Short term debt 6.02M 0.05M 6.61M 0.05M 1.15M
Short long term debt 5.95M - 6.61M 0.05M 1.15M
Short long term debt total 6.31M 0.02M 6.61M 0.05M 1.15M
Other stockholder equity 95.24M 45.10M 24.72M 22.21M 18.07M
Total current assets 1.39M 2.20M 1.27M 0.73M 0.03M
Net receivables - 0.15M - - -
Accounts payable 7.11M 3.52M 2.96M 1.34M 0.54M
Non currrent assets other 0.57M 1.20M - - -
Non current assets total 1.43M 1.22M 0.00M 0.00M 0.00M
Capital lease obligations 0.36M 0.02M 0.00M - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total cashflows from investing activities -0.50M - - - -
Net borrowings 3.70M 0.10M 1.37M -0.21M 0.25M
Total cash from financing activities 20.86M 4.25M 1.28M 1.49M 0.25M
Net income -62.15M -11.90M -14.92M -3.05M -3.38M
Change in cash -0.01M 0.03M -0.60M 0.61M -0.15M
Begin period cash flow 0.06M 0.03M 0.63M 0.03M 0.17M
End period cash flow 0.06M 0.06M 0.03M 0.63M 0.03M
Total cash from operating activities -20.36M -4.21M -1.88M -0.88M -0.40M
Issuance of capital stock 17.16M 4.62M 0.00M 2.40M 0.00M
Depreciation 0.04M 0.25M 0.00M - -
Change to account receivables - - - 0.00M 0.08M
Other cashflows from financing activities - -0.47M -0.09M -0.70M -
Capital expenditures 0.50M 0.00M 0.00M 0.00M 0.00M
Change in working capital 2.14M 1.49M 1.71M 0.67M 0.66M
Stock based compensation 35.56M 0.00M 0.00M 1.29M 2.22M
Other non cash items 4.05M 5.95M 11.33M 0.21M 0.10M
Free cash flow -20.86M -4.21M -1.88M -0.88M -0.40M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
NTHI
NeOnc Technologies Holdings, Inc. Common Stock		 0.03
0.66%		 4.55 - - 2384.24 - 2681.65
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38

Profile*

NeOnc Technologies Holdings, Inc. Common Stock

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.

23975 Park Sorrento, Calabasas, CA, United States, 91302

310 663 7831

https://www.neonc.com

5

Name Title Year Born
Mr. Amir Farrokh Heshmatpour President, CEO, Executive Chairman & Secretary 1967
Dr. Thomas C. Chen M.D., Ph.D. Founder, Chief Medical Officer, Chief Scientific Officer & Vice Chairman 1965
Mr. Keithly A. Garnett Chief Financial Officer 1975
Dr. Josh Neman-Ebrahim Ph.D. Chief Clinical Officer 1978
Mr. David Choi Jr. Chief Accounting Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 106.39
+7.88%
GRZ
CAD 4.80
+5.26%
CTC
CAD 226.00
+4.63%
CAE
CAD 40.63
+4.21%
FEC
CAD 7.26
+3.57%
FSZ
CAD 2.40
-15.79%
TF
CAD 4.56
-11.28%
ITR
CAD 2.71
-9.67%
LAR
CAD 5.23
-7.43%
BZ
CAD 4.00
-7.41%

Equity Sectors*

  • Basic Materials

    -2.89%

  • Communication Services

    +0.25%

  • Consumer Cyclical

    +0.37%

  • Consumer Defensive

    -0.02%

  • Energy

    -0.30%

  • Financial Services

    -1.06%

  • Healthcare

    -0.73%

  • Industrials

    -0.49%

  • Real Estate

    +0.22%

  • Technology

    -1.52%

  • Utilities

    +0.08%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…